OrthoSpin

Company Overview

Snapshot

Founded in December 2014 by Yoni Epstein, OrthoSpin operated with 1–10 employees. The company raised $8 million across 3 funding rounds from 2 investors, including Johnson & Johnson Innovation. OrthoSpin was acquired by DePuy Synthes in November 2021.

Business overview

OrthoSpin developed a smart external fixation system designed to enhance orthopedic treatment by providing real-time physician follow-up and reducing patient compliance dependency. Its core technology involved a robotic strut with a lightweight motor and control box, which automatically and continuously adjusted and lengthened the struts on a circular hexapod fixation frame. The company's proprietary software allowed physicians to monitor patient progress and modify treatment schedules. OrthoSpin operated within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Therapeutics, serving the healthcare provider market.

Strategic signal

OrthoSpin's acquisition by DePuy Synthes in November 2021 signifies a strategic validation of its robotic external fixation technology within the orthopedic market. This exit demonstrates the value placed on automated, digitally-enabled solutions that improve patient outcomes and streamline treatment protocols, suggesting a growing trend towards integrating smart medical devices into established healthcare systems.

Company Intelligence Q&A

When was OrthoSpin acquired?

OrthoSpin was acquired by DePuy Synthes in November 2021.

Which investors participated in OrthoSpin's Series B financing round?

In March 2020, OrthoSpin secured Series B financing from Johnson & Johnson Innovation and The Trendlines Group.

When did OrthoSpin receive FDA clearance for its G2 system?

OrthoSpin received FDA regulatory clearance for its second-generation robotic, digitally enabled external fixation system (G2 system) in January 2021.

What was a key feature of OrthoSpin's technology?

OrthoSpin's system allowed physicians to chart patient progress and modify treatment schedules via proprietary software, ensuring the prescribed course of treatment was followed automatically without direct patient intervention.